Exudative AMD subtypes and eligibility for treatment with ranibizumab

S. George; C. Cooke; Usha Chakravarthy

doi:10.1038/eye.2009.301

Exudative AMD subtypes and eligibility for treatment with ranibizumab

S. George, C. Cooke, Usha Chakravarthy

Research output: Contribution to journal › Article

15 Citations (Scopus)

Abstract

Purpose To ascertain the proportion of patients with neovascular age-related macular degeneration (AMD) eligible for intravitreal treatment with monoclonal antibodies to vascular endothelial growth factor, on the basis of inclusion criteria used in pivotal clinical trials.

Original language	English
Pages (from-to)	1247-1251
Number of pages	5
Journal	Eye
Volume	24
Issue number	7
DOIs	https://doi.org/10.1038/eye.2009.301
Publication status	Published - Jul 2010

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1038/eye.2009.301

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Exudative AMD subtypes and eligibility for treatment with ranibizumab'. Together they form a unique fingerprint.

Cite this

@article{3879c0c6f9ac4ea095df965fae469e46,

title = "Exudative AMD subtypes and eligibility for treatment with ranibizumab",

abstract = "Purpose To ascertain the proportion of patients with neovascular age-related macular degeneration (AMD) eligible for intravitreal treatment with monoclonal antibodies to vascular endothelial growth factor, on the basis of inclusion criteria used in pivotal clinical trials.",

author = "S. George and C. Cooke and Usha Chakravarthy",

year = "2010",

month = jul,

doi = "10.1038/eye.2009.301",

language = "English",

volume = "24",

pages = "1247--1251",

journal = "Eye",

issn = "0950-222X",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Exudative AMD subtypes and eligibility for treatment with ranibizumab

AU - George, S.

AU - Cooke, C.

AU - Chakravarthy, Usha

PY - 2010/7

Y1 - 2010/7

N2 - Purpose To ascertain the proportion of patients with neovascular age-related macular degeneration (AMD) eligible for intravitreal treatment with monoclonal antibodies to vascular endothelial growth factor, on the basis of inclusion criteria used in pivotal clinical trials.

AB - Purpose To ascertain the proportion of patients with neovascular age-related macular degeneration (AMD) eligible for intravitreal treatment with monoclonal antibodies to vascular endothelial growth factor, on the basis of inclusion criteria used in pivotal clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=77954726273&partnerID=8YFLogxK

U2 - 10.1038/eye.2009.301

DO - 10.1038/eye.2009.301

M3 - Article

VL - 24

SP - 1247

EP - 1251

JO - Eye

JF - Eye

SN - 0950-222X

IS - 7

ER -